This research study is studying different immunotherapy regimens as a possible treatment for
stage III or IV resectable melanoma.
This research study is a Phase II clinical trial. Phase II clinical trials test the safety
and effectiveness of an investigational drug to learn whether the drug works in treating a
specific disease. "Investigational" means the drug is being studied.
The FDA (the U.S. Food and Drug Administration) has approved OPDIVO® (nivolumab), YERVOY®
(ipilimumab), and a combination of the two as treatment options for metastatic melanoma.
The FDA (the U.S. Food and Drug Administration) has not approved the combination of nivolumab
and BMS-986205 as a treatment for any disease. This research study is looking for more
information on the efficacy the combination of nivolumab and BMS-986205 in the treatment of
Nivolumab, Ipilimumab, and BMS-986205 are types of immunotherapy. Immunotherapy works by
encouraging the body's own immune system to attack the cancer cells. Nivolumab, Ipilimumab,
and BMS-986205 work by stopping various molecules on cancer cells and body cells from working
against the immune system's natural fight against cancer.
In this research study, the investigators are going to look at the following while the
participants are receiving the study drug(s):
• The effectiveness (how well the drug works), safety, and tolerability of Nivolumab,
BMS-986205 and Nivolumab, and Ipilimumab and Nivolumab in people with resectable stage III or
- Histologic or cytologic diagnosis of resectable stage III or IV cutaneous melanoma.
Patients with melanoma of mucosal origin are not eligible. Patients with acral
melanoma that fit criteria are eligible. Patients must have clinically detectable
stage III (clinically detectable N1b, N1c, N2b, N2c, N3b or N3c) or stage IV
- Age ≥ 18 years.
- ECOG performance status ≤2 (Karnofsky ≥60%, see Appendix A)
- Participants must have normal organ and marrow function as defined below:
- leukocytes ≥2,000/mcL
- absolute neutrophil count ≥1,500/mcL
- platelets ≥100,000/mcL
- hemoglobin ≥9.0g/dL
- total bilirubin within normal institutional limits
- AST(SGOT)/ALT(SGPT) ≤2.5 × institutional upper limit of normal
- creatinine within normal institutional limits OR
- creatinine clearance ≥40 mL/min/1.73 m2 for participants with creatinine levels
above institutional normal.
- C-Reactive Protein < institutional ULN
- Quantitative or qualitative G6PD assay results must not suggest underlying G6PD
- Measurable disease (by CT, PET/CT or MRI)
- Prior therapies including targeted therapy and immunotherapy are not allowed, with the
exception of adjuvant Ipilimumab or Interferon-α-2b.
- Ability to understand and the willingness to sign a written informed consent document.
- Ability to swallow pills intact and without GI issues which may impact medication
- Women of childbearing potential (WOCBP) must agree to follow instructions for
method(s) of contraception (Refer to Appendix B) for the duration of treatment with
study treatment(s) plus 5 months post-treatment completion (i.e. 30 days plus the time
required for nivolumab to undergo approximately 5 half-lives).
- Women of childbearing potential (WOCBP) must have a negative serum or urine pregnancy
test (minimum sensitivity 25 IU/L or equivalent units of HCG) within 24 hours prior to
the start of study treatment.
- Males who are sexually active with WOCBP must agree to follow instructions for
method(s) of contraception for the duration of treatment with study treatment(s) plus
7 months post-treatment completion (i.e. 90 days plus the time required for nivolumab
to undergo approximately 5 half-lives). In addition, male participants must be willing
to refrain from sperm donation during this time. This criterion applies to azoospermic
males as well.
- A history of prior treatment with PD-1 inhibitor, CTLA-4 inhibitor or IDO inhibition.
Prior therapy with ipilimumab or Interferon-α-2b in the adjuvant setting is permitted.
Participants may not have received live/attenuated vaccines within 30 days of first
- Participants with uveal or mucosal melanoma
- Participants with known brain metastases must have documented stability for at least
30 days directly prior to study enrollment and not be requiring active treatment for
these. Prior radiation, surgery and stereotactic radiosurgery are allowed but must be
completed four weeks prior to initiating therapy.
- History of allergic reactions attributed to compounds of similar chemical or biologic
composition to nivolumab, ipilimumab, methylene blue or BMS-986205. History or
presence of hypersensitivity or idiosyncratic reaction to methylene blue.
- Need for systemic steroids at the time of enrollment. Physiologic replacements at a
dose of less than 10 mg daily prednisone equivalent is allowed.
- Blood Methemoglobin > ULN, assessed in an arterial or venous blood sample or by
- Participants with active ILD/pneumonitis or history of ILD/ pneumonitis requiring
- Uncontrolled intercurrent illness including, but not limited to, ongoing or active
infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac
arrhythmia, or psychiatric illness/social situations that would limit compliance with
- Pregnant women are excluded from this study because there is an unknown but potential
risk for adverse events in nursing infants secondary to treatment of the mother with
nivolumab or BMS-986205, breastfeeding should be discontinued if the mother is treated
with nivolumab or BMS-986205. These potential risks may also apply to other agents
used in this study.
- Known active HIV, Hepatitis B or Hepatitis C patients. HIV-positive participants on
combination antiretroviral therapy are ineligible because of the potential for an
immunologic effect with the therapy. Appropriate studies will be undertaken in
participants receiving combination antiretroviral therapy when indicated.
- Autoimmune disease that requires treatment at the time of enrollment. Participants
with type I diabetes mellitus, hypothyroidism only requiring hormone replacement, skin
disorders (such as vitiligo, psoriasis, or alopecia) not requiring systemic treatment
or conditions not expected to recur in the absence of an external trigger are
permitted to enroll.
- Participant with a personal or family (ie, in a first-degree relative) history of
cytochrome b5 reductase deficiency (previously called methemoglobin reductase
deficiency) or other diseases that put them at risk of methemoglobinemia. All
participants will be screened for methemoglobin levels prior to randomization.
- Participant with a history of G6PD deficiency or other congenital or autoimmune
hemolytic disorders. All participants will be screened for G6PD levels prior to
- Participants must not have a history of life-threatening toxicity related to prior
immune therapy (eg. anti-CTLA-4 or any other antibody or drug specifically targeting
T-cell co-stimulation or immune checkpoint pathways) except those that are unlikely to
re-occur with standard countermeasures (eg. hormone replacement after adrenal crisis).
- Treatment with botanical preparations (eg, herbal supplements or traditional Chinese
medicines) intended for general health support or to treat the disease under study
within 2 weeks prior to randomization.
- History of other malignancy within 3 years prior to screening, with the exception of
those with a negligible risk of metastasis or death (e.g., 5-year OS of > 90%), such
as adequately treated carcinoma in situ of the cervix, non-melanoma skin carcinoma,
localized prostate cancer, ductal carcinoma in situ, or Stage I uterine cancer.
- Participants who have had major surgery requiring general anesthesia or significant
trauma who have not recovered per physician determination for at least 14 days prior
- Participants with conditions known to interfere significantly with the absorption of
oral medication, as per investigator judgment.
- Participants with uncontrolled adrenal insufficiency.
- Prior history of serotonin syndrome.